These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9637748)

  • 21. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
    Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
    Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of foot and mouth disease virus by RT-PCR and microplate hydridization assay using inactivated viral antigens.
    Barlic-Maganja D; Grom J; Toplak I; Hostnik P
    Vet Res Commun; 2004 Feb; 28(2):149-58. PubMed ID: 14992244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines.
    Brown F
    Dev Biol Stand; 1991; 75():37-41. PubMed ID: 1665462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of the seven serotypes of foot-and-mouth disease virus by reverse transcriptase polymerase chain reaction.
    Callens M; De Clercq K
    J Virol Methods; 1997 Aug; 67(1):35-44. PubMed ID: 9274816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of foot-and-mouth disease virus, its genome and proteins at 37 degrees C.
    Razdan R; Sen AK; Rao BV; Suryanarayana VV
    Acta Virol; 1996 Feb; 40(1):9-14. PubMed ID: 8886092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of foot-and-mouth disease vaccines containing endonuclease-inactivated virions.
    Amadori M; Barei S; Melegari M; Panina GF
    Vaccine; 1987 Sep; 5(3):219-22. PubMed ID: 2823495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enteroviral ribonucleic acid. II. Biological, physical, and chemical studies.
    HOLLAND JJ; McLAREN LC; HOYER BH; SYVERTON JT
    J Exp Med; 1960 Nov; 112(5):841-64. PubMed ID: 13715282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of foot-and-mouth disease virus vaccine strains by activation of virus-associated endonuclease.
    Scodeller EA; Lebendiker MA; Dubra MS; Crespo OA; Basarab O; La Torre JL; Vasquez C
    J Gen Virol; 1984 Sep; 65 ( Pt 9)():1567-73. PubMed ID: 6088682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
    Ben-Hur E; Chan WS; Yim Z; Zuk MM; Dayal V; Roth N; Heldman E; Lazo A; Valeri CR; Horowitz B
    Dev Biol (Basel); 2000; 102():149-55. PubMed ID: 10794102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of 3-imino-5-phenyl-3H-1,2-dithiole on poliovirus type 1 replication in vitro.
    Garozzo A; Pinizzotto MR; Furneri PM; Baratta D; Guerrera F; Castro A; Tornetta B; Geremia E
    Antiviral Res; 1990; 14(4-5):267-77. PubMed ID: 1965112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the inactivation and antigenicity of foot-and-mouth-disease virus by acetylethyleneimine and by combined effect of ultraviolet light and beta-propiolactone.
    Fellowes ON
    J Immunol; 1965 Dec; 95(6):1100-6. PubMed ID: 4285068
    [No Abstract]   [Full Text] [Related]  

  • 34. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.
    Vignuzzi M; Stone JK; Andino R
    Virus Res; 2005 Feb; 107(2):173-81. PubMed ID: 15649563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid and sensitive polymerase chain reaction based detection and typing of foot-and-mouth disease virus in clinical samples and cell culture isolates, combined with a simultaneous differentiation with other genomically and/or symptomatically related viruses.
    Vangrysperre W; De Clercq K
    Arch Virol; 1996; 141(2):331-44. PubMed ID: 8634024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and sensitive detection of foot-and-mouth disease virus in tissues by enzymatic RNA amplification of the polymerase gene.
    Meyer RF; Brown CC; House C; House JA; Molitor TW
    J Virol Methods; 1991; 34(2):161-72. PubMed ID: 1666635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of biopharmaceutical market-appropriate plastic syringe barrel for extractables.
    DeGrazio F; Runkle J; Smythe J; Miller A
    PDA J Pharm Sci Technol; 2009; 63(4):360-7. PubMed ID: 20088249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and immunogenic variations among closely related isolates of foot-and-mouth disease virus.
    Martinez MA; Carrillo C; Plana J; Mascarella R; Bergada J; Palma EL; Domingo E; Sobrino F
    Gene; 1988; 62(1):75-84. PubMed ID: 2453395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.